{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+inhaler&page=2",
    "query": {
      "intervention": "Placebo inhaler",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 295,
    "total_pages": 30,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+inhaler&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+inhaler&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-01T03:30:36.773Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05649748",
      "title": "An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "Treprostinil Palmitil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insmed Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2023-03-07",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-01T03:30:36.773Z",
      "location_count": 6,
      "location_summary": "Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05649748"
    },
    {
      "nct_id": "NCT02796677",
      "title": "AMPLIFY - D6571C00001 Duaklir USA Phase III Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)",
          "type": "DRUG"
        },
        {
          "name": "Aclidinium bromide 400 μg (AB 400 μg)",
          "type": "DRUG"
        },
        {
          "name": "Formoterol fumarate 12 μg (FF 12 μg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg",
          "type": "OTHER"
        },
        {
          "name": "Tiotropium 18 μg (TIO 18 μg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo to TIO 18 μg",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "40 Years to 130 Years"
      },
      "enrollment_count": 1595,
      "start_date": "2016-07-05",
      "completion_date": "2017-06-08",
      "has_results": true,
      "last_update_posted_date": "2018-11-09",
      "last_synced_at": "2026-10-01T03:30:36.773Z",
      "location_count": 85,
      "location_summary": "Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more",
      "locations": [
        {
          "city": "Gulf Shores",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02796677"
    },
    {
      "nct_id": "NCT03015259",
      "title": "Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Budesonide/Formoterol fumarate dihydrate",
          "type": "DRUG"
        },
        {
          "name": "Symbicort",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kindeva Drug Delivery",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1762,
      "start_date": "2016-12-29",
      "completion_date": "2018-02-08",
      "has_results": true,
      "last_update_posted_date": "2022-08-24",
      "last_synced_at": "2026-10-01T03:30:36.773Z",
      "location_count": 95,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 74 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03015259"
    },
    {
      "nct_id": "NCT00749411",
      "title": "Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "GSK233705/GW642444",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 61,
      "start_date": "2008-11-13",
      "completion_date": "2009-02-12",
      "has_results": true,
      "last_update_posted_date": "2020-09-01",
      "last_synced_at": "2026-10-01T03:30:36.773Z",
      "location_count": 12,
      "location_summary": "Mobile, Alabama • Wheat Ridge, Colorado • Biddeford, Maine + 9 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Wheat Ridge",
          "state": "Colorado"
        },
        {
          "city": "Biddeford",
          "state": "Maine"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Summit",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00749411"
    },
    {
      "nct_id": "NCT04059094",
      "title": "A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "BI 1265162",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2019-09-16",
      "completion_date": "2020-04-24",
      "has_results": true,
      "last_update_posted_date": "2021-06-04",
      "last_synced_at": "2026-10-01T03:30:36.773Z",
      "location_count": 8,
      "location_summary": "Orlando, Florida • Indianapolis, Indiana • Chapel Hill, North Carolina + 5 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04059094"
    },
    {
      "nct_id": "NCT05798923",
      "title": "LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Hypertension Due to Lung Diseases and Hypoxia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "LAM-001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OrphAI Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 85,
      "start_date": "2023-08-30",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-01T03:30:36.773Z",
      "location_count": 32,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05798923"
    },
    {
      "nct_id": "NCT01143688",
      "title": "Characterization of Placebo Responses in Stable Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Asthma Placebo Effects"
      ],
      "interventions": [
        {
          "name": "albuterol",
          "type": "DRUG"
        },
        {
          "name": "placebo inhaler",
          "type": "DRUG"
        },
        {
          "name": "placebo acupuncture",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 39,
      "start_date": "2005-01",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-30",
      "last_synced_at": "2026-10-01T03:30:36.773Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01143688"
    },
    {
      "nct_id": "NCT00669617",
      "title": "Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Indacaterol",
          "type": "DRUG"
        },
        {
          "name": "Salmeterol/fluticasone (50/500 μg)",
          "type": "DRUG"
        },
        {
          "name": "Salbutamol (200 µg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Indacaterol",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Salmeterol/fluticasone",
          "type": "DRUG"
        },
        {
          "name": "Placebo to salbutamol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2008-04",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2011-09-12",
      "last_synced_at": "2026-10-01T03:30:36.773Z",
      "location_count": 5,
      "location_summary": "Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more",
      "locations": [
        {
          "city": "Tamarac",
          "state": "Florida"
        },
        {
          "city": "Lafayette",
          "state": "Louisiana"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        },
        {
          "city": "Beaver",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00669617"
    },
    {
      "nct_id": "NCT02061202",
      "title": "Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Mometasone Furoate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeffrey Glassberg",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2014-03",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2019-03-11",
      "last_synced_at": "2026-10-01T03:30:36.773Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02061202"
    },
    {
      "nct_id": "NCT00877383",
      "title": "Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Indacaterol 150 μg",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium 18 μg",
          "type": "DRUG"
        },
        {
          "name": "Placebo to indacaterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 1142,
      "start_date": "2009-04",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2011-08-25",
      "last_synced_at": "2026-10-01T03:30:36.773Z",
      "location_count": 116,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 102 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00877383"
    }
  ]
}